EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cytomegalovirus Prevention in Liver Transplant Recipients: A Comparative Study of Universal and Preemptive Strategies with Valganciclovir

Mohsen Aliakbarian, Faezeh Majidianfar, Seyed Sajjad Alavi Kakhki, Saeed Javanshir, Mandana Khodashahi, Kambiz Akhavan Rezayat, Maliheh Dadgar Moghadam, Mahboobeh Ghasemzadeh Rahbardar, Rozita Khodashahi

Archives of Clinical Infectious Diseases · 23.02.2026 · 21 (1)

DOI: 10.5812/archcid-158027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Clinical Infectious Diseases, online erschienen am 23.02.2026. Verfasst von Mohsen Aliakbarian und 8 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives: Universal prophylaxis and preemptive therapy are established strategies to prevent cytomegalovirus (CMV) after liver transplantation, yet their real-world comparative performance varies by center and risk mix.

Methods

We conducted a single-center retrospective cohort of consecutive adult recipients transplanted from 2013 - 2021 in Mashhad, Iran. Exposure was the CMV-prevention strategy received (universal valganciclovir prophylaxis vs preemptive PCR-based monitoring). Primary outcomes were CMV viremia (PCR-confirmed) and CMV disease (clinical/histologic). Secondary outcomes were late-onset CMV (> 100 days post-transplant), acute rejection, and mortality. Multivariable logistic regression (and Cox proportional hazards where event dates were available) adjusted for calendar era, donor/recipient serostatus (D/R), immunosuppression regimen, monitoring protocol, age, and sex.

Results

Among 475 recipients (universal valganciclovir: 170; preemptive monitoring: 305), CMV viremia occurred in 10/170 (5.9%) vs 18/305 (5.9%) (P = 0.993). Among the 28 infected patients, 23 (82.1%) were male. Onset timing was < 1 month in 6 (21.4%), 1 - 3 months in 9 (32.1%), and > 6 months in 13 (46.4%), indicating late-onset (> 3 months) in 22/28 (78.6%) overall.

Conclusions

In this cohort, universal prophylaxis and preemptive monitoring showed no significant adjusted differences in CMV infection or disease. Given era effects and center-specific practices, policy selection should consider D/R risk, monitoring logistics, and late-onset CMV risk. Multicenter studies are warranted.

Zitieren

APA

Aliakbarian, M., Majidianfar, F., Kakhki, S. S. A., Javanshir, S., Khodashahi, M., Rezayat, K. A., Moghadam, M. D., Rahbardar, M. G., & Khodashahi, R. (2026). Cytomegalovirus Prevention in Liver Transplant Recipients: A Comparative Study of Universal and Preemptive Strategies with Valganciclovir. Archives of Clinical Infectious Diseases, 21(1). https://doi.org/10.5812/archcid-158027

Vancouver

Aliakbarian M, Majidianfar F, Kakhki SSA, Javanshir S, Khodashahi M, Rezayat KA, et al. Cytomegalovirus Prevention in Liver Transplant Recipients: A Comparative Study of Universal and Preemptive Strategies with Valganciclovir. Archives of Clinical Infectious Diseases. 2026;21(1). doi:10.5812/archcid-158027

BibTeX
@article{Aliakbarian2026,
  author = {Aliakbarian, Mohsen and Majidianfar, Faezeh and Kakhki, Seyed Sajjad Alavi and Javanshir, Saeed and Khodashahi, Mandana and Rezayat, Kambiz Akhavan and Moghadam, Maliheh Dadgar and Rahbardar, Mahboobeh Ghasemzadeh and Khodashahi, Rozita},
  title = {Cytomegalovirus Prevention in Liver Transplant Recipients: A Comparative Study of Universal and Preemptive Strategies with Valganciclovir},
  journal = {Archives of Clinical Infectious Diseases},
  year = {2026},
  volume = {21},
  number = {1},
  doi = {10.5812/archcid-158027}
}
Kostenlos starten →